Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

• Published in: Oral oncology 2021-04, Vol.115, p.105192-105192, Article 105192
• Main Authors: Adkins, Douglas R., Lin, Jin-Ching, Sacco, Assuntina, Ley, Jessica, Oppelt, Peter, Vanchenko, Vyacheslay, Komashko, Nataliia, Yen, Chia-Jui, Wise-Draper, Trisha, Lopez-Picazo Gonzalez, Jose, Radulovic, Sinisa, Shen, Qi, Thurm, Holger, Martini, Jean-François, Hoffman, Justin, Huang, Xin, Melichar, Bohuslav, Tahara, Makoto
• Format: Article
• Language: English
• Subjects: Cetuximab; Head and neck cancer; Palbociclib; Squamous cell carcinoma
• ISSN: 1368-8375; 1879-0593
• DOI: 10.1016/j.oraloncology.2021.105192

•Median overall survival (OS) was 9.7 months with palbociclib (PAL)+cetuximab (CET).•Median OS was 7.8 months with placebo (PBO)+CET (HR = 0.82, P = 80.18 vs PAL+CET).•OS was longer than expected in the PBO+CET group.•Treatment-related adverse events were more common in the PAL+CET group. This study examined whether palbociclib and cetuximab prolonged overall survival (OS) versus placebo and cetuximab. In this double-blind, randomized, phase 2 trial (PALATINUS), patients with platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent/metastatic head and neck squamous-cell carcinoma received cetuximab and either palbociclib (arm A) or placebo (arm B). The primary endpoint was OS; 120 patients were required to have ≥80% power to detect a hazard ratio (HR) of 0.6 (median OS of 10 months in arm A and 6 months in arm B) using a one-sided, log-rank test (P = 0.10). 125 patients were randomized (arm A: 65, arm B: 60). Median follow-up was 15.9 months (IQR, 11.3–22.7). Median OS was 9.7 months in arm A and 7.8 months in arm B (HR, 0.82; 95% CI, 0.54–1.25; P = 0.18). Median progression-free survival was 3.9 months in arm A and 4.6 months in arm B (HR, 1.00; 95% CI, 0.67–1.5; P = 0.50). The most common treatment-related adverse events in arm A were rash (39 patients, 60.9%) and neutropenia (26, 40.6%; three febrile) and in arm B was rash (32, 53.3%). There was no significant difference in median OS with palbociclib and cetuximab versus placebo and cetuximab. Pfizer Inc (NCT02499120).